Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

Crizotinib is an effective drug for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), but upon treatment, the tumors inevitably become crizotinib resistant in time. The resistance mechanisms are only partly understood. In this study, we aim to identify gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jiacong, van der Wekken, Anthonie J., Saber, Ali, Terpstra, Miente M., Schuuring, Ed, Timens, Wim, Hiltermann, T. Jeroen N., Groen, Harry J. M., van den Berg, Anke, Kok, Klaas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789360/
https://www.ncbi.nlm.nih.gov/pubmed/29300322
http://dx.doi.org/10.3390/cancers10010010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789360/
https://www.ncbi.nlm.nih.gov/pubmed/29300322
http://dx.doi.org/10.3390/cancers10010010

Ejemplares similares